Progen to license cancer R&D
Wednesday, 18 September, 2002
Drug developer Progen Industries is licensing development rights to a new patented cancer therapy from the University of New South Wales.
The agreement with the university's commercialisation arm, UniQuest, gives Progen exclusive world rights to technology covering a novel drug formulation and delivery mechanism with the potential to treat multiple cancers.
Progen is already in trials with its flagship anti-cancer drug, PI-88. It sees the newly-licensed therapy, labelled PI-166, as a complementary stablemate to PI-88 which will help fill Progen's drug pipeline.
PI-166 is currently in late-stage pre-clinical development and Progen will fund further R&D, including human trials, to provide further validation of the therapy.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
